Isolation and characterization of anticancer compound from sesuvium portulacastrum (l.) l.
OwnerSathvika Chintalapani, Lakshmi Narasu Mangamooriinventors
Life of this patent
Estimating the term…
Abstract
The invention discloses a novel anticancer compound, 3, 4, 5-trimethyl-2-(4-(8-methylnonyl)phenyl)pyridine extracted from Sesuvium portulacastrum (S. portulacastrum) having the structure as represented by Formula (I). The invention also discloses a method of extraction of this anticancer compound, 3, 4, 5-trimethyl-2-(4-(8-methylnonyl)phenyl)pyridine from S. portulacastrum. The invention further relates to characterization of the anticancer compound, 3, 4, 5-trimethyl-2-(4-(8-methylnonyl)phenyl)pyridine and study of its effect on the cancer cell cycle progression and expression of genes involved in apoptosis.
Claims12
A compound of Formula (I)
- or a pharmaceutically acceptable salt thereof.
A process for the isolation of compound of Formula (I) from Sesuvium portulacastrum,
- said process comprising the steps of:
- i. obtaining powder of dried whole plant of Sesuvium portulacastrum,
- ii. extracting the powdered Sesuvium portulacastrum with one or more solvent,
- iii. concentrating the extract obtained in step (ii) to obtain crude extract,
- iv. optionally, fractionating the crude extract by column chromatography,
- v. separating and purifying the crude extract obtained in step (iii) or the fractions obtained in step (iv) by preparative TLC and
- vi. isolating the compound of Formula (I).
A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of Formula (I) and one or more pharmaceutical excipient.
Use of compound of Formula (I) or a pharmaceutically acceptable salt thereof for the treatment of cancer
A method for treating cancer in a subject comprising administering an effective amount of compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.